Metadoro
Products
News and analysis

News and analysis

Check market insights shared by our community members

09.01.2025

VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025

Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

23.01.2025

Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

16.01.2025

Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025

Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

Rafael Quintana Martinez

Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/

11.08.2025

Tron Is Preparing for a Jump

Tron (TRX) is up 0.9% this week to $0.3410, trailing behind Bitcoin (BTC), which has gained 2.3% to $121,430. The broader market rally was bolstered by U.S. President Donald Trump’s executive order permitting digital assets such as Bitcoin in 401k retirement plans—a move that opens a vast new pool of capital. The U.S. retirement market is valued at around $43 trillion, meaning even a 1% allocation would surpass the size of all existing crypto ETFs combined.

This policy shift has already injected fresh capital into the market, helping Bitcoin reach new all-time highs. Tron could follow suit in the coming days, targeting $0.3500, with a potential acceleration toward $0.4000 if that resistance breaks. Such levels may present a favourable window for profit-taking.

TRXUSD

528

Rafael Quintana Martinez

08.08.2025

Monero Slumps amid Qubic Mining War

Monero (XMR) is down 11.9% this week to $266.50, significantly underperforming the broader crypto market, where Bitcoin (BTC) has gained 1.9% to $116,543. The sharp drop in XMR is mainly linked to the ongoing Qubic-XMR mining conflict, which has sparked concerns over a potential 51% network hashrate takeover. Since these concerns surfaced in late July, Monero has shed 21% of its value.

Despite dipping to $256.4, which marks the midpoint of its current upward channel, XMR quickly rebounded suggesting resilience and the potential for a steeper recovery. If the support around $275.0 continues to hold, this could pave the way for a move higher, with an eventual target around $325.0.

XMRUSD

512

Bash

08.08.2025

Eli Lilly Seeks Brave Hands

A rare happy good luck! For anyone who has long been looking for a high-quality US asset with at least $500 billion in market capitalization, but much cheaper than what people call a "fair price". Eli Lilly delivered a stunning second-quarter financial performance, by far shattering all its previous records once again and beating already too hot and much elevated consensus estimates for the profitability of its best-selling weight-loss drug by 12.88%. But its stock price suddenly plunged nearly 15% due to a quite controversial clinical miss of a new oral pill. I don't tell you to grab the first price found on the street tomorrow morning, but a procrastinating delay for too long would be even a bigger mistake.

Eli Lilly was a measly $30 shy of hitting $1,000 at its 2024 peaking price and about $80 distance short of touching that same milestone in 2025. And it's currently trading below $650, which means another $300 of headroom for nearly 50% of the future recovery potential. Perhaps the fortune will grant us an even lower price, but for me it's very unlikely that the asset may fall below $600 for more than a day. Here are some major details, and you draw your own conclusions.

To be very brief, the company's main profit has so far been made by anti-diabetic and weight loss products under the Zepbound and Mounjaro brands, and they have broken all previous records and average expectations once again. Those key medications are in the forms of injections. Together, they provided sales that grew to $10.40 billion, with Mounjaro generating $5.20 billion (up 68% YoY) and Zepbound contributing $3.38 billion (up 172% YoY). This is a unique achievement. No competitors like NovoNordisk, whose drugs reportedly and allegedly have unacceptable side effects like vision damage, can even come close to Eli Lilly's current achievement. Its EPS (earnings per share) jumped 92% YoY to $6.29 against $3.92 in the same period of 2024 and the previous record of $5.32 in Q4 2024. Beside that, Lilly raised its full-year sales guidance by another $1.5 billion to a higher range of $60 billion to $62 billion, also raising its inner profit expectations to $20.85-$22.10 per share.

This is all on the positive side. So what else could the market want? First, a few months ago the crowd wound itself up with even higher expectations, which prevented the $1000 from being taken by storm and brought about a rollback and correction phase. However, that would be only half the self-made trouble for too brave investing minds. And the other half of the same trouble is that Eli Lilly has vowed to make and promote a very effective pill so that patients do not have to take injections. And the market has too high hopes for that pill. Morgan Stanley experts, for example, estimated the financial effect of the pill revenue at an extra $40 billion each year by 2033. But the most recent weight loss pill trial effect was modest compared to high market bets. In particular, the last phase of a clinical trial led the group of patients to lose an average weight of 12.4% (27.3 pounds) over 72 weeks. 59.6% of all participants lost at least 10% of their corresponding body weight and 39.6% lost even 15% or more. Despite this being statistically significant, specialists expected even higher results.I don't know what you'll say, but for me, I'd rather swallow one pill a day than inject myself in the stomach or anywhere else, even if the pills would burn off my weight more slowly. The company also emphasized that its innovative pill (named orforglipron) still represents a significant advancement as a "once-daily oral therapy that could support early intervention and long-term obesity management, though the commercial opportunity may be more limited than originally anticipated".

Well, you can do whatever you want, but next week I’m personally buying a few shares of Eli Lilly for my mostly tech portfolio, without looking at the particular share price at all. And if it suddenly falls below $600 for a while, then I’ll buy the same amount more of Eli Lilly and I'll wait for the $950 or higher target as long as it takes. A typical situation for brave hands. Remember when CrowdStrike shares nearly collapsed because of a stupid computer glitch that "buried" Windows on 19 July 2024. There was a huge price discount, with CRWD share price plunging to $200 per share. So what? Less than a year passed, and CrowdStrike shares were breaking new records above $500, as if nothing had happened. The same will happen with Eli Lilly.

LLY

597

Rafael Quintana Martinez

07.08.2025

Large Investors Still Support Dogecoin

Dogecoin (DOGE) is up 3.3% this week to $0.2065, outperforming the broader crypto market, where Bitcoin (BTC) has gained a modest 0.15% to $114,530. DOGE surged 29.3% in July, reaching $0.2125 and peaking at $0.2875 before retreating amid broader negative market sentiment. Despite the pullback, the overall monthly performance highlights the memecoin’s underlying strength.

August has brought renewed pressure, but strong support from large investors at the key $0.2000 level reinforces the bullish outlook. If this support continues to hold, the next upside target remains $0.3000, a level that would mark a significant continuation of DOGE’s recovery trend.

DOGUSD

721